Enterprise Therapeutics Ltd, a Brighton, England, UK-based drug discovery company, closed a £4m (approx. $5m) funding.
The round was led by existing investors Epidarex Capital and Imperial Innovations.
The company intends to use the funds to accelerate its three drug discovery projects towards drug candidate selection.
Led by Dr John Ford, CEO, Enterprise Therapeutics is dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
In more details, the company is developing novel muco-regulatory therapies for patients suffering with cystic fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and severe asthma. All of this is done by targeting mechanisms that increase the clearance of mucus or reduce levels of mucus production in order to alleviate the symptoms and complications associated with respiratory disease.